Fezolinetant

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Hot Flashes

Drug Information

Target Indication

Hot Flashes

Clinical Trial

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA12/7/2023

Veoza

Veoza is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

Drug Science

Mechanism of action & safety profile

Developer

ALPMY

Astellas Pharma

Related Pipeline

Clostridium Difficile

Kidney Transplantation

Pancreatic Cancer

Post Operative Pain

Fungemia

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts